Can Berberine Naturally Boost Glucagon-like Peptide-1 (GLP-1) to Impact Blood Glucose Level and Body Weight Reduction?

Berberine, a natural isoquinoline alkaloid, is increasingly recognized for its therapeutic effects on metabolic disorders, specifically its ability to regulate blood glucose and reduce body weight by influencing glucagon-like peptide-1 (GLP-1) levels (M. Rondanelli et al., 2023). This ancient compound, utilized in traditional medicine for centuries, provides a compelling natural alternative to modern pharmaceuticals due to its broad bioactivity and favorable safety profile (A. Cicero & Alessandra Baggioni, 2016). Scientific inquiry continues to uncover the intricate molecular pathways through which berberine exerts its beneficial metabolic effects, emphasizing its capacity to enhance GLP-1 secretion and modulate critical physiological processes (Weili Yang et al., 2024).

The Role of GLP-1 in Metabolic Regulation

GLP-1 is a key incretin hormone produced by intestinal L cells in response to nutrient intake. It plays a crucial role in maintaining glucose homeostasis and energy balance (Ard, Jamy et al. 2021). Its primary function involves stimulating glucose-dependent insulin secretion from pancreatic beta-cells, which effectively lowers post-meal blood glucose levels (Ard, Jamy et al. 2021). Beyond its direct impact on insulin, GLP-1 also suppresses glucagon secretion, slows gastric emptying, and promotes satiety by acting on appetite control centers in the brain, all of which contribute to improved glycemic control and reduced caloric intake, leading to weight loss (Ard, Jamy et al. 2021). These diverse physiological actions underscore GLP-1's significance as a therapeutic target for managing conditions such as type 2 diabetes and obesity (Ard, Jamy et al. 2021).

Berberine's Mechanism of Action on GLP-1 Levels

Studies have consistently shown that berberine increases plasma GLP-1 levels, particularly after oral glucose administration (Weili Yang et al., 2024). This elevation in GLP-1 is pivotal to Berberine's efficacy in improving glucose metabolism and insulin sensitivity (Weili Yang et al., 2024). Research indicates that berberine promotes GLP-1 biosynthesis by increasing the expression of proglucagon mRNA in intestinal endocrine cells (2021). This direct effect on GLP-1 production is a primary mechanism through which berberine exerts its antidiabetic properties (Ard, Jamy et al. 2021).

 

Furthermore, berberine is believed to stimulate GLP-1 secretion by activating bitter taste receptors (TAS2Rs) and associated phospholipase C (PLC)-dependent pathways within intestinal L cells (Y Yu et al., 2015). Additionally, berberine’s metabolites, such as berberrubine and palmatine, have been demonstrated to significantly enhance GLP-1 production and glucose-stimulated secretion in GLUTag cells, suggesting a complex metabolic interplay involving both the parent compound and its active derivatives (Weili Yang et al., 2024). The compound also alleviates oxidative stress and mitochondrial dysfunction in L cells, which are crucial for optimal GLP-1 secretion (Weili Yang et al., 2024).

 

 

Figure 1: Mechanisms of Berberine-Induced GLP-1 Secretion and Metabolic Effects.

This schematic illustrates the molecular mechanisms by which berberine enhances glucagon-like peptide-1 (GLP-1) secretion and contributes to glycemic control and weight reduction. Berberine increases GLP-1 production through upregulation of pro-glucagon mRNA expression, activation of bitter taste receptors (TAS2Rs), and reduction of oxidative stress in intestinal L cells. Elevated GLP-1 levels stimulate insulin secretion from pancreatic β-cells, delay gastric emptying, and promote satiety, collectively contributing to reduced blood glucose levels and body weight. These actions position berberine as a potential natural adjunct to current GLP-1-based therapies for metabolic disorders.

 

Impact on Blood Glucose and Body Weight

The increased GLP-1 levels induced by berberine directly contribute to its effectiveness in blood glucose regulation. By stimulating GLP-1, berberine enhances glucose-dependent insulin secretion, facilitating the uptake of glucose into cells for energy (Ard, Jamy et al. 2021). Clinical trials have reported that berberine supplementation significantly reduces fasting plasma glucose (FPG) and 2-hour postprandial glucose (2hPG) levels, along with glycated hemoglobin (HbA1c), in patients with prediabetes and type 2 diabetes (M. Rondanelli et al., 2023). Moreover, berberine has been shown to decrease insulin levels and improve insulin resistance, further contributing to better glycemic control (M. Rondanelli et al., 2023).

Berberine's ability to lower fasting glucose and HbA1c stems from its multifaceted actions, including its effect on GLP-1. By increasing GLP-1, berberine enhances glucose-dependent insulin release from the pancreas, which helps clear glucose from the bloodstream, thereby reducing fasting glucose levels. Additionally, GLP-1 suppresses glucagon secretion, preventing the liver from producing excessive glucose, further contributing to lower fasting glucose. The cumulative effect of improved insulin sensitivity, reduced glucose production, and enhanced glucose utilization over time is reflected in a significant reduction in HbA1c, which serves as a long-term indicator of blood glucose control.

Beyond glucose regulation, GLP-1's actions in the brain to dampen "food noise" and reduce hunger, coupled with its effect on delaying gastric emptying, lead to prolonged satiety and can result in weight loss (Dr. Bojana Jankovic Weatherly, 2025). Berberine also directly influences fat metabolism, acting as an anti-adipogenic agent by suppressing the regulation of transcription factors vital for fat tissue growth, such as peroxisome proliferator-activated receptor gamma (PPARG), CCAAT enhancer binding protein α (C/EBPα), and sterol response element binding protein-1c (SREBP-1c) (AR. Utami et al., 2023). Clinical studies confirm that berberine consumption can lead to significant reductions in visceral adipose tissue and overall fat mass in overweight individuals (M. Rondanelli et al., 2023). This makes berberine a compelling subject for further investigation as a natural compound for metabolic health.

Recent FDA Approvals and the Future of GLP-1 Agonists

The pronounced success of GLP-1-based therapies has led to numerous FDA approvals for managing type 2 diabetes and obesity (Kommu S et al., 2025; Dr. Bojana Jankovic Weatherly, 2025). Semaglutide, available as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, are prominent examples of FDA-approved GLP-1 receptor agonists (Kommu S et al., 2025; Dr. Bojana Jankovic Weatherly, 2025). Oral semaglutide (Rybelsus), approved in 2019, offers a non-injectable alternative (Kommu S et al., 2025). Notably, the FDA approved tirzepatide (Zepbound) for chronic weight management in November 2023, marking a significant advancement in addressing the obesity epidemic (Dr. Bojana Jankovic Weatherly, 2025).

While these synthetic GLP-1 agonists have demonstrated remarkable efficacy in clinical trials, they are associated with a range of side effects, including common gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation, which are often dose-dependent (Kommu S et al., 2025; Dr. Bojana Jankovic Weatherly, 2025). More severe but less frequent adverse events can include gallbladder issues and pancreatitis (Kommu S et al., 2025; Dr. Bojana Jankovic Weatherly, 2025). Concerns persist regarding the long-term safety profile of these medications, potential muscle mass loss, nutrient deficiencies, and the challenge of weight regain upon discontinuation, which often necessitates lifelong treatment (Dr. Bojana Jankovic Weatherly, 2025). Furthermore, the FDA has recently halted the sale of off-brand, compounded GLP-1 medications due to safety and purity concerns, emphasizing the importance of approved formulations (CNN, 2025).

Berberine, as a natural compound that indirectly modulates GLP-1 levels, presents a promising area for further research, especially given its generally mild side effect profile, primarily limited to gastrointestinal discomfort (M. Rondanelli et al., 2023). Its multifaceted mechanisms of action and established efficacy in numerous metabolic parameters warrant continued investigation (Weili Yang et al., 2024). Future research into berberine, including the development of new formulations with improved bioavailability and novel derivatives, could lead to innovative and accessible therapeutic strategies for metabolic disorders, complementing the evolving landscape of GLP-1-based interventions.

It is interesting to note that Berberine's ability to influence GLP-1 and enhance insulin sensitivity closely resembles the mechanism of action of metformin, a widely used medication for type 2 diabetes. As a natural compound, berberine may present a compelling alternative for those seeking a less synthetic approach to metabolic health. It potentially has fewer and milder side effects compared to prescription drugs. This natural origin contributes to its perceived safety, making it an appealing option for individuals looking to support their metabolic well-being.

Legal Disclaimer

Reference:

1. Rondanelli, M., Gasparri, C., Petrangolini, G., Allegrini, P., Avenoso, D., Fazia, T., Bernardinelli, L., Peroni, G., Patelli, Z., Mansueto, F., Tartara, A., Cavioni, A., & Riva, A. (2023). Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. European review for medical and pharmacological sciences, 27(14), 6718–6727.

2. Cicero, A. F., & Baggioni, A. (2016). Berberine and Its Role in Chronic Disease. Advances in experimental medicine and biology, 928, 27–45.

3. Yang, W. L., Zhang, C. Y., Ji, W. Y., Zhao, L. L., Yang, F. Y., Zhang, L., & Cao, X. (2024). Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction. The American journal of Chinese medicine, 52(1), 253–274. 

4. Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021). Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. Advances in therapy, 38(6), 2821–2839.

5. Yang, W. L., Zhang, C. Y., Ji, W. Y., Zhao, L. L., Yang, F. Y., Zhang, L., & Cao, X. (2024). Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction. The American journal of Chinese medicine, 52(1), 253–274.

6. Rondanelli, M., Gasparri, C., Petrangolini, G., Allegrini, P., Avenoso, D., Fazia, T., Bernardinelli, L., Peroni, G., Patelli, Z., Mansueto, F., Tartara, A., Cavioni, A., & Riva, A. (2023). Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. European review for medical and pharmacological sciences, 27(14), 6718–6727.

7. Yu, Y., Hao, G., Zhang, Q., Hua, W., Wang, M., Zhou, W., Zong, S., Huang, M., & Wen, X. (2015). Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways. Biochemical pharmacology, 97(2), 173–177.

8. Bojana Jankovic Weatherly, Melissa Reade. (2025) Assessing the Benefits, Risks, and Long-Term Metabolic Effects of GLP-1 Agonists, Cardiometabolic Health (https://drbojana.com/assessing-the-benefits-risks-and-long-term-metabolic-effects-of-glp-1-agonists/)

9. Utami, A. R., Maksum, I. P., & Deawati, Y. (2023). Berberine and Its Study as an Antidiabetic Compound. Biology, 12(7), 973.

10. Kommu S, Whitfield P. Semaglutide. [Updated 2024 Feb 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/

11. CNN. (2025, May 21). FDA cracks down on compounded semaglutide and tirzepatide. https://www.cnn.com/2025/05/21/health/fda-compounded-semaglutide-tirzepatide-crackdown